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OBJECTIVES We analyzed the regulatory function of reactive oxygen species (ROS) on the hypertrophic
signaling in adult rat cardiac myocytes.
BACKGROUND The ROS regulate mitogenic signal transduction in various cell types. In neonatal rat cardiac
myocyte, antioxidants have been shown to inhibit cardiac hypertrophy, and ROS are
suggested to modulate the hypertrophic signaling. However, the conclusion may not reflect
the situation of mature heart, because of the different natures between neonatal and adult
cardiac myocytes.
METHODS Cultured adult rat cardiac myocytes were stimulated with endothelin-1 (ET-1) or phenyl-
ephrine (PE), and intracellular ROS levels, the activities of mitogen-activated protein kinases
(MAPKs; ERK, p38, and JNK), and 3H-phenylalanine incorporation were examined. We
also examined the effects of antioxidant pretreatment of myocytes on MAPK activities and
cardiac hypertrophy to analyze the modulatory function of redox state on MAPK-mediated
hypertrophic signaling.
RESULTS The ROS levels in ET-1- or PE-stimulated myocytes were maximally increased at 5 min after
stimulation. The origin of ROS appears to be from NADH/NADPH oxidase, because the
increase in ROS was suppressed by pretreatment of myocytes with NADH/NADPH oxidase
inhibitor diphenyleneiodonium. Extracellular signal-regulated kinase (ERK) activity was
increased by the stimulation of ET-1 or PE. In contrast, p38 and c-Jun-N-terminal protein
kinase (JNK) activities did not change after these stimulations. Antioxidant treatment of
myocytes suppressed the increase in ROS and blocked ERK activation and the subsequent
cardiac hypertrophy induced by these stimuli.
CONCLUSIONS These data demonstrate that ROS mediate signal transduction of cardiac hypertrophy
induced by ET-1 or PE in adult rat cardiac myocytes. (J Am Coll Cardiol 2001;37:676–85)
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Oxygen free radicals or reactive oxygen species (ROS) have
been implicated in the pathogenesis of a variety of diseases
such as hypoxia-reperfusion injury and drug-induced car-
diomyopathy. Recent studies revealed that oxidative stress is
increased in patients with congestive heart failure (1) and in
cardiac hypertrophy model following decompensation (2).
In these situations, ROS have been generally considered to
be toxic to the cells. However, recent studies have demon-
strated that ROS play a role as second messengers to
regulate mitogenic signal transduction in various cell types,
such as smooth muscle cells, endothelial cells, and fibro-
blasts (3).
Cardiac hypertrophy is at least initially an adaptive
reaction of the heart against cardiac overloading to maintain
cardiac function. As mentioned above, it was reported that
ROS are implicated in the transition of compensated
hypertrophy to heart failure. In the late stage of cardiac
hypertrophy, ROS appear to be toxic for myocardium and
induce myocardial dysfunction or injury. Conversely, very
few studies have evaluated the role of ROS in the early stage
of cardiac hypertrophy. Of interest is a recent report
suggesting that antioxidants inhibited neonatal rat cardiac
myocyte hypertrophy (4). This suggests the possibility that
ROS are involved in the hypertrophic signaling. However,
the exact mechanism of how ROS are involved in the
signaling pathways of cardiac hypertrophy remains to be
elucidated. Furthermore, neonatal cardiac myocytes, which
have been widely used for the experimental cardiac hyper-
trophy models, proved to be different from mature adult
cardiac myocytes in several respects (5,6).
In this study we have evaluated the hypothesis that ROS
might alter the activities of mitogen-activated protein kinase
(MAPK) pathways and might modulate the subsequent
development of cardiac hypertrophy in adult rat myocytes.
To address this question, in the present study we examined
ROS levels and MAPK activities in endothelin-1 (ET-1)-
or phenylephrine (PE)-stimulated myocytes, and we ana-
lyzed the modulatory function of redox state on MAPK-
mediated hypertrophic signaling pathways.
METHODS
Cardiac myocyte isolation and culture. Adult rat cardiac
myocytes were isolated from 10-week-old Sprague-Dawley
rats as described previously (7). Isolated myocytes were
suspended in the M199 culture medium supplemented with
2 mg/ml bovine serum albumin, 2 mmol/liter carnitine, 5
mmol/liter creatine, 5 mmol/liter taurine, 100 IU/ml pen-
icillin, and 100 mg/ml streptomycin, and were plated on
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laminin-coated 35-mm dishes. The culture medium was
exchanged for fresh medium to remove the damaged myo-
cytes that failed to attach 2 h after plating. After this
procedure, 80% to 90% myocytes were viable and showed
rod-shape.
Neonatal rat cardiac myocytes were harvested from 2–3-
day-old Sprague-Dawley rats by trypsin and collagenase
digestion, purified by differential preplating, and cultured in
D-MEM/F-12 culture medium supplemented with
2 mg/ml bovine serum albumin, 10 mg/liter insulin, 5.5
mg/liter transferrin, 6.7 mg/liter selenium, 100 IU/ml
penicillin, and 100 mg/ml streptomycin.
All experiments in this study were performed on the next
day after plating.
Incorporation of 3H-phenylalanine. For the evaluation of
cardiac hypertrophy, 3H-phenylalanine (Amersham Chem-
ical, Arlington Heights, Illinois) incorporation into myo-
cytes was measured. 3H-phenylalanine (10 mCi) was added
to each dish. After 12 h incubation, myocytes were recov-
ered, treated with TCA, and 3H-phenylalanine incorpora-
tion into myocytes was measured by liquid scintillation
counter. Where indicated, PE (Sigma Chemical, St. Louis,
Missouri) or ET-1 (Sigma Chemical) was added simulta-
neously with or without the treatment of 2 mmol/liter
N-acetylcysteine (NAC; Sigma Chemical).
Measurements of reactive oxygen species (ROS). After
the stimulation of myocytes with ET-1 or PE, intracellular
ROS levels were measured using dichlorofluroescein (DCF)
as described previously with some modifications (8). Briefly,
after these stimulations, culture medium was exchanged for
Krebs-Ringer bicarbonate buffer (KRB; composition in
mmol/liter: NaCl, 110; KCl, 2.6; KH2PO4, 1.2; MgSO4,
1.2; NaHCO3, 25; pyruvate, 5; taurin, 30; HEPES, 20; and
glucose, 11, pH 7.4). The DCF-diacetate (5 mg/ml; Mo-
lecular Probes, Eugene, Oregon) was loaded to myocytes for
5 min at 37°C. Myocytes were subsequently imaged under
fluorescence microscope (Olympus OSP-3; Olympus, To-
kyo, Japan), and fluorescence of DCF was quantified. In
certain cases, cells were treated with 2 mmol/liter of NAC,
50 U/ml of catalase, 1 mmol/liter of mitochondrial electron
transport inhibitor rotenone (Nacalai Tesque, Kyoto, Ja-
pan), or 2.5 mmol/liter of NADH/NADPH oxidase inhib-
itor diphenyleneiodonium chloride (DPI; Calbiochem-
Novabiochem, La Jolla, California) for 1 h before
assessment with DCF. For each condition, fluorescence
intensity was measured from at least 30 individual cells.
Levels of lipid peroxides in myocytes were also measured
after these stimulations for 12 h using a lipid peroxidation
assay kit (Calbiochem-Novabiochem) according to the
manufacturer’s recommendation.
The MAPK assay. The activities of MAPKs (extracellular
signal-regulated kinase [ERK], c-Jun-N-terminal protein
kinase [JNK], and p38) were determined by Western blot
analysis using polyclonal antibodies that recognize only
phosphorylated MAPKs (phospho-ERK, phospho-JNK,
and phospho-p38 antibodies; New England Biolabs, Bev-
erly, Massachusetts). Quantitative analysis of MAPK activ-
ities was performed using densitometer.
The LDH assay. To examine the cytotoxicity of antioxi-
dant NAC, myocytes were incubated with 2 mmol/liter
NAC for 12 h, culture medium was recovered, and the
lactate dehydrogenase (LDH) assay was performed using
Cytotoxicity Detection Kit (Boehringer Mannheim, Mann-
heim, Germany).
Statistical analysis. Differences between groups were ana-
lyzed by one-way analysis of variance using the Dunnett or
Bonferroni procedure. Results are expressed as mean 6 SD.
A value of p , 0.05 was considered statistically significant.
RESULTS
The ROS levels in cardiac hypertrophy. For the demon-
stration of our hypothesis that hypertrophic singling is
mediated by ROS, we measured ROS levels in cardiac
myocytes when cells were stimulated by ET-1 or PE. Figure
1 shows the time course of ROS levels after the stimulation
of 1027 mol/liter ET-1 (Fig. 1A) or 10 mmol/liter PE (Fig.
1B). Both ET-1 and PE increased ROS levels in cardiac
myocytes; ROS levels were maximal at 5 min and declined
to basal level by 30 min after stimulation. This increase in
ROS levels was also evident by an increase in lipid peroxi-
dation in ligand-stimulated myocytes (Fig. 2).
The origin of ROS. To confirm the antioxidant effect of
NAC and catalase, and to determine the localization of
ROS origin, myocytes were pretreated with NAC (2 mmol/
liter), catalase (50 U/ml), mitochondrial electron transport
inhibitor rotenone (1 mmol/liter), or NADH/NADPH
oxidase inhibitor diphenyleneiodonium chloride (DPI, 2.5
mmol/liter) for 1 h before the stimulation of ET-1 or PE,
and DCF fluorescence was measured. As seen in Figure 3,
both NAC and catalase significantly inhibited the increase
in DCF fluorescence of myocytes stimulated by ET-1 or
PE. The increase in DCF fluorescence induced by ET-1 or
PE was inhibited by DPI, however, and not by rotenone.
These data are consistent with a NADH/NADPH oxidase
as a potential source of the origin of ligand-stimulated ROS.
The MAPK activities. We examined the effects of ET-1
and PE on MAPK activities. The time course of MAPK
activities when adult cardiac myocytes were stimulated with
ET-1 is shown in Figure 4A. The ERK activity was
DCF 5 dichlorofluorescein
DPI 5 diphenyleneiodonium chloride
ERK 5 extracellular signal-regulated kinase
ET 5 endothelin
JNK 5 c-Jun-N-terminal protein kinase
LDH 5 lactate dehydrogenase
MAPK 5 mitogen-activated protein kinase
NAC 5 N-actylcysteine
PE 5 phenylephrine
ROS 5 reactive oxygen species
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Figure 1. Time course of DCF fluorescence in adult rat cardiac myocytes stimulated with (A) endothelin-1 (ET) or (B) phenylephrine (PE). Fluorescence
intensity was measured from at least 30 individual cells. Data are shown as mean 6 SD. *p , 0.05 compared to control.
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maximal at 5 min after ET-1 stimulation. However, p38
and JNK activities showed no changes after ET-1 stimula-
tion. The activities of p38 and JNK were also not stimulated
by the treatment of myocytes with anisomycin or UV light
exposure, which are strong activators of these kinases in
other types of cells. In contrast, in neonatal cardiac myocytes
(Fig. 4B), p38 and JNK activities were stimulated by ET-1,
anisomycin treatment, or UV light exposure. The ERK
activity showed similar change to that of adult cardiac
myocytes. In neonatal cardiac myocytes, p38 activity re-
mained elevated at least for 60 min, and JNK activity was
maximal at 5 min after ET-1 stimulation. Similar results
were obtained when myocytes were stimulated with PE
(data not shown).
Redox regulation of MAPK activities. To define the
mechanism of how ROS modulate hypertrophic singling,
we examined the effects of chemical antioxidant NAC and
H2O2 scavenger catalase on ERK activity. Myocytes were
pretreated with NAC (2 mmol/liter) or catalase (50 U/ml)
for 1 h, and ET-1, PE, or phorbol-12-myristate-13-acetate
(PMA), an activator of protein kinase C, was added to
culture medium. After 5-min stimulation by these agents,
cells were recovered and ERK activity was examined by
Western blotting. As shown in Figure 5, the increased
activity of ERK induced by ET-1 or PE was significantly
suppressed by catalase or NAC treatment. However, the
enhanced activity of ERK by PMA was not suppressed by
these antioxidants. This result demonstrates that redox
regulation is capable of altering the activity of ET-1- or
PE-dependent MAPK pathway in adult rat cardiac myo-
cytes.
Redox regulation of cardiac hypertrophy. Finally, we
examined the effect of antioxidant NAC on cardiac hyper-
trophy induced by ET-1 or PE. Incorporation of 3H-
phenylalanine into adult rat cardiac myocytes was signifi-
cantly increased by the stimulation of endothelin-1 (ET-1)
or phenylephrine (PE) in a dose-dependent manner (Fig.
6). As shown in Figure 7, the increase in 3H-phenylalanine
incorporation into myocytes stimulated by 1027 mol/liter
ET-1 or 10 mmol/liter PE was significantly inhibited by the
treatment of myocytes with N-acetylcysteine (NAC). Al-
though NAC can affect the viability of certain cells, at the
concentration used we noted no toxicity as assessed by LDH
release. The LDH activity released from NAC-treated
myocytes showed no significant difference from that re-
leased from control myocytes (absorbance; NAC: 0.206 6
0.019, control: 0.200 6 0.005).
Taken together, these results demonstrate that in adult
rat cardiac myocytes, ROS regulate hypertrophic signaling
at least in part by modulating the activities of MAPK
cascade.
DISCUSSION
We demonstrated that ET-1 and PE increase ROS levels
and induce hypertrophy of adult rat cardiac myocytes, and
Figure 2. The reactive oxygen species (ROS) levels in cardiac myocytes stimulated with endothelin (ET) or phenylephrine (PE). The ROS levels were
measured by lipid peroxidation assay. Data are shown as mean 6 SD. n 5 5, *p , 0.05 compared to control (C).
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that ET-1- and PE-induced hypertrophy is inhibited by the
treatment of cardiac myocytes with chemical antioxidant
NAC. These data support the hypothesis that ROS mediate
hypertrophic signaling of cardiac myocytes.
The role of ROS in cardiac hypertrophy. Recent clinical
and experimental studies demonstrated that oxidative stress
plays an important role in the transition of cardiac hyper-
trophy to heart failure (1,2). Although the exact mecha-
nisms of how ROS are involved in both early and late stages
of cardiac hypertrophy are not clear, we propose that low
levels of ROS may be essential to regulate the response of
cardiac myocytes to hypertrophic stimuli. In contrast, at the
late stage of cardiac hypertrophy when the production of
ROS significantly exceeds the capacity of an antioxidant
defense system such as superoxide dismutase (SOD), glu-
tathione peroxidase and catalase, ROS levels increase in
large amounts and may induce myocardial dysfunction
and/or injury.
Redox regulation of MAPK pathways and cardiac hyper-
trophy. Our data demonstrate that the chemical antioxi-
dant NAC and H2O2 scavenger catalase suppressed ERK
activity stimulated by ET-1 or PE, although these antioxi-
dants did not suppress the activity of ERK enhanced by
PMA. The data supports the hypothesis that ROS regulate
hypertrophic signaling at least in part by modulating the
activities of ET-1- or PE-dependent MAPK pathways in
cardiac myocytes. Our experiments using NADH/NADPH
oxidase inhibitor diphenyleneiodonium chloride (DPI) and
the mitochondrial electron transport inhibitor rotenone
showed that the origin of ET-1- or PE-induced ROS might
be from NADH/NADPH oxidase in the cell membrane. It
is likely that the direct effect of ROS may be on the
upstream of the MAPK pathways that exists in the cell
membrane or its near site, given that ROS are highly
reactive and short-lived.
Previous studies have demonstrated that ROS can mod-
ulate multiple signaling pathways upstream of nuclear tran-
scription factors, including Ca21 signaling in vascular
smooth muscle cells (VSMCs) (9) protein phosphorylation
such as tyrosine kinases in a variety of cell types (10) and
MAPK in VSMCs (11). Direct regulatory effects of ROS
on transcription factor activities such as AP-1 and NF-kB
have also been demonstrated in several cell types (12). In the
present study, one of the mechanisms of how ET-1- or
PE-induced cardiac hypertrophy is inhibited by NAC may
be due to the suppressive effect of NAC on the MAPK
cascade. There may be other possibilities that ROS modu-
late the activity of phosphotidylinositol 3-kinase pathway,
Figure 3. Effects of N-actylcysteine (NAC), catalase, rotenone, or diphenyleneiodonium chloride (DPI) on reactive oxygen species (ROS) levels in myocytes
stimulated by endothelin (ET) or phenylephrine (PE). The dichlorofluorescein (DCF) fluorescence intensity was measured from at least 30 individual cells.
Data are shown as mean 6 SD. *p , 0.05.
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Ca21 signaling or transcription factor activities such as
AP-1, and thus regulate hypertrophic signaling in ET-1- or
PE-stimulated cardiac myocytes. Further studies are re-
quired to define these mechanisms.
Adult versus neonatal cardiac myocyte. In the present
study using adult rat cardiac myocytes, ET-1 or PE stimu-
lated the activity of ERK; however, these agents did not
stimulate the activities of either p38 or JNK. In contrast,
previous studies using neonatal rat cardiac myocytes showed
that these stimuli enhance the activities of all these MAPKs
(13). Our data using neonatal cardiac myocytes are consis-
tent with the results of these studies. Although the reasons
for the different results between adult and neonatal cardiac
myocytes are not clear, one obvious explanation may be due
to intrinsic differences between neonatal and adult rat
cardiac myocytes. Adult cardiac myocytes have no mitogenic
properties, and they are considered to be terminally differ-
entiated cells.
In contrast, neonatal cardiac myocytes are still capable of
proliferating after birth; therefore, they are not regarded as
Figure 4. Time course of mitogen-activated protein kinase (MAPK) activities after the stimulation of myocytes with endothelin (ET) in adult (A) and
neonatal cardiac myocytes (B). Myocytes were also treated with anisomycin (10 mg/ml) for 1 h, or exposed to UV light for 30 min, and phospho-p38 and
phospho-JNK expression were also examined. As a positive control for phospho-p38, total cell extracts from anisomycin-treated C-6 glioma cells, which
are commercially available (Cell Signaling Technology, Beverly, Massachusetts), were used. As a positive control for phospho-JNK, total cell extracts from
293 cells prepared with UV light treatment (Cell Signaling Technology, Beverly, Massachusetts) were used.
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Figure 5. Effects of catalase and N-actylcysteine (NAC) on enhanced extracellular signal-regulated kinase (ERK) activity induced by endothelin (ET),
phenylephrine (PE), or phorbol-12-myristate-13-acetate (PMA) in adult cardiac myocytes. Activated ERK was detected by Western blot analysis using
antibody against phospho-ERK. To confirm that equal amounts of protein were loaded for each lane, membrane was stripped and Western blotting using
antibody against whole ERK was performed again. Quantitative analysis was performed using densitometer. Fold activations of phospho-ERK compared
to control are expressed as mean 6 SD; n 5 5. *p , 0.05.
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Figure 6. Dose-dependent increase in 3H-phenylalanine incorporation into myocytes stimulated by endothelin (ET) (A) or phenylephrine (PE) (B).
Percentage of incorporation compared to control was expressed as mean 6 SD; n 5 5. *p , 0.05.
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terminally differentiated cells. Furthermore, recent studies
revealed different responses to hypertrophic stimuli between
neonatal and adult cardiac myocytes in addition to differ-
ences in cell size and structure, metabolism, gene expression,
and receptor composition (5,6). We believe that adult rat
cardiac myocytes are more appropriate for the molecular
analysis of hypertrophy of mature heart.
Clinical benefit of antioxidant therapy. Recent clinical
and experimental studies have demonstrated that ROS are
involved in the pathogenesis of heart failure (14) and that
vitamin E supplementation prevents the development of
heart failure in an animal model (2). The beneficial effects of
a beta-blocker that has antioxidant properties in patients
with heart failure have also been reported (15). In the
present study, we demonstrated that ROS play an important
role in the signaling of hypertrophy in adult rat cardiac
myocytes at least in part by modulating the activities of
MAPK pathways. These data suggest a potential benefit of
antioxidant therapy as inhibitors of cardiac hypertrophy.
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